NASDAQ:PACB - Pacific Biosciences Stock Price, Price Target & More

Pacific Biosciences trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences (NASDAQ:PACB) posted its quarterly earnings results on Thursday, February, 1st. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. The biotechnology company earned $24.94 million during the quarter, compared to analyst estimates of $21.89 million. Pacific Biosciences had a negative net margin of 98.63% and a negative return on equity of 98.98%. The company's quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.21) EPS. View Pacific Biosciences' Earnings History.

Pacific Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Pacific Biosciences.

3 Wall Street analysts have issued 1-year target prices for Pacific Biosciences' stock. Their predictions range from $4.00 to $8.00. On average, they expect Pacific Biosciences' share price to reach $6.2667 in the next year. View Analyst Ratings for Pacific Biosciences.

Pacific Biosciences saw a decrease in short interest in the month of March. As of March 29th, there was short interest totalling 10,469,372 shares, a decrease of 19.4% from the March 15th total of 12,986,469 shares. Based on an average daily trading volume, of 1,118,752 shares, the short-interest ratio is presently 9.4 days. Approximately 9.0% of the company's stock are sold short.

Some companies that are related to Pacific Biosciences include Rocket Pharmaceuticals (RCKT), Omeros (OMER), Triple-S Management (GTS), Anika Therapeutics (ANIK), New England Nuclear (LNTH), AMAG Pharmaceuticals (AMAG), RadNet (RDNT), Novavax (NVAX), Endocyte (ECYT), Hanger (HNGR), Mesa Laboratories (MLAB), Jounce Therapeutics (JNCE), Tactile Systems Technology (TCMD), Lannett (LCI), Addus HomeCare (ADUS), Reata Pharmaceuticals (RETA), Dicerna Pharmaceuticals (DRNA) and Heska (HSKA).

Media stories about PACB stock have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pacific Biosciences earned a coverage optimism score of 0.10 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.81 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $2.59.

Pacific Biosciences has a market capitalization of $341.55 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences employs 456 workers across the globe.

Pacific Biosciences' mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]